Accelerating the valorisation of the BEAT inflammation technology, a microbiome-based biotherapeutic for chronic respiratory inflammatory diseases. (BEAT inflammation)

This project aims to increase the IP value and industrial partner attractiveness of the UGent BEAT technology, which offers an innovative approach to treat inflammation in patients with chronic lung disease. Although a scientific proof-of-concept has been established by the UGent research team, particular gaps remain to be addressed from an industry perspective. Hence, the proposed StarTT project aims to fill the gap between an academic and industry proof-of-concept.